drugset / Trial / NCT05580341
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
Phase 3
Unknown
1200 enrolled
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd. · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
This study will evaluate the immunogenicity and safety of Zerun 9-valent HPV recombinant vaccine in healthy female 16-26 years of age by comparing with GARDASIL®9.
Timeline
- Start
- 2022-09-01
- Primary completion
- 2023-06
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gardasil 9 | Vaccine | 0.5 ml | — |
| Subject | Zerun HPV-9 | Vaccine | 0.5 ml | — |